PMID- 23409519
OWN - NLM
STAT- MEDLINE
DCOM- 20130827
LR  - 20191112
IS  - 0350-199X (Print)
IS  - 0350-199X (Linking)
VI  - 66
IP  - 6
DP  - 2012
TI  - Tamsulosin efficiency in treatment of benign prostatic hyperplasia evaluated by 
      determining bladder weight.
PG  - 391-5
AB  - INTRODUCTION/GOAL: Bladder wall thickness and bladder mass are higher in patients 
      with subvesical obstruction caused by benign prostate enlargement (BPE) in 
      compensated stage of the disease. The goal of the study was to determine changes 
      of bladder detrusor in patients suffering from benign prostatic hyperplasia (BPH) 
      during tamsulosin treatment. The study was open, prospective and multi-centric. 
      MATERIAL AND METHODS: The material in this study was composed of 20 patients, 
      aged > 45 years, with the present lower urinary tract symptoms (LUTS) caused by 
      benign prostatic hyperplasia, who had not been treated for the previous 3 months. 
      The inclusive criteria also included the value of International Prostate Symptom 
      Score (IPSS) > or = 8 points, post-void residual urine volume (PVR) < 100 ml and 
      prostate specific antigen (PSA) < 4 ng/ml. After the end of the trials that were 
      necessary for the introduction of the patients in the study, the patients started 
      taking tamsulosin in a daily dosage of 0.4 mg, and the evaluation parameters 
      during the research were measured at time intervals of 4, 12 and 24 weeks. The 
      evaluation parameters were primary and secondary. The primary parameter included 
      ultrasound estimated bladder weight (UEWB), while the secondary included 
      determination of the blood pressure values (RR) and pulse frequency (PF), of 
      total International Prostate Symptom Score (T-IPSS), a part of IPSS that related 
      to the storage symptoms (I-PSS), a part that related to the voiding symptoms 
      (O-IPSS), quality of life determination (IPSS-QoL), ultrasound estimation of 
      prostate volume (VP) and the quantity of post-void residual urine volume (PVR), 
      along with the determination of the number and strength of adverse reactions. 
      RESULTS: During the introduction of the patients in the trial, the arithmetic 
      mean of UEWB was 65 g, of PVR 43 ml, VP 35 ml, of total T-IPSS 15.6 points, of 
      I-IPSS 6.9 points, of O-IPSS 8.7 points, and of IPSS-QoL 3.6 points. During the 
      four-week, twelve-week and twenty-four-week checkups, the values were the 
      following: the arithmetic mean of UEWB 36, 39 and 28 grams, of PVR 26, 29 and 21 
      ml, of T-IPSS 8.3, 6.4 and 5.0 points, of IPSS 3.8, 3.0 and 2.4 points, of O-IPSS 
      4.6, 3.4 and 2.6 points, of IPSS-QoL 1.7, 1.1 and 1.0 points and of VP 34 ml 
      during the last control. The obtained results of this trial were processed by 
      descriptive statistics (arithmetic mean and standard deviation) and analytical 
      statistics by way of Student's t-test for dependant (paired) samples, with the 
      comparison made between the obtained results with the zero checkup and four-week 
      checkup, and subsequently the comparison between four-week and twelve-week 
      checkup, twelve-week and twenty-four week checkup, and the zero checkup and the 
      twenty-four week checkup. Adverse drug reactions (libido and ejaculation problems 
      5% and headache 5%) were mild and tolerant and did not require the interruption 
      of the therapy. CONCLUSION: During a 24-week treatment of benign prostatic 
      hyperplasia with tamsulosin, the same showed clinical efficiency in the sense of 
      improvement of LUTS and a decrease of bladder outlet obstruction (BOO), without 
      the influence on prostate volume or showing statistically significant 
      vasodilatory effect. The same affected a significant decrease of ultrasound 
      estimated bladder weight (from 65 g to 28 g).
FAU - Milicevic, Snjezana
AU  - Milicevic S
AD  - Urologic Clinic, Clinical Center Banja Luka, Banja Luka, Bosnia and Herzegovina.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - Bosnia and Herzegovina
TA  - Med Arch
JT  - Medical archives (Sarajevo, Bosnia and Herzegovina)
JID - 101635337
RN  - 0 (Adrenergic alpha-1 Receptor Antagonists)
RN  - 0 (Sulfonamides)
RN  - G3P28OML5I (Tamsulosin)
SB  - IM
MH  - Adrenergic alpha-1 Receptor Antagonists/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Organ Size/drug effects
MH  - Prostate/drug effects/pathology
MH  - Prostatic Hyperplasia/*drug therapy/pathology
MH  - Quality of Life
MH  - Sulfonamides/*therapeutic use
MH  - Tamsulosin
MH  - Urinary Bladder/*drug effects/pathology
EDAT- 2013/02/16 06:00
MHDA- 2013/08/28 06:00
CRDT- 2013/02/16 06:00
PHST- 2013/02/16 06:00 [entrez]
PHST- 2013/02/16 06:00 [pubmed]
PHST- 2013/08/28 06:00 [medline]
AID - 10.5455/medarh.2012.66.391-395 [doi]
PST - ppublish
SO  - Med Arch. 2012;66(6):391-5. doi: 10.5455/medarh.2012.66.391-395.